Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...

Better known by Novo Nordisk's brand names Ozempic and Wegovy (the former of which is indicated only for type 2 diabetes), ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral density loss.

Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's ...

open image in gallery A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, (REUTERS/Hollie Adams/File Photo ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Vivani Medical Provides Business Update Including $5M Equity Financing and Reports Third Quarter 2024 Financial Results ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

The position in Novo Nordisk hindered returns as the company’s Wegovy obesity treatment missed revenue expectations due to a ...

The agency is also evaluating Novo Nordisk’s (NVO) semaglutide drugs for the same label. After significant pushback, the FDA ...

GLP-1 agonists – of which Novo Nordisk’s Ozempic and Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide) are the most ...